In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 4, 1999, Pages 405-410

  Higashikawa, Fumiko ^a   Murakami, Teruo ^a   Kaneda, Tatsuya ^a   Takano, Mikihisa ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLOTRIMAZOLE; CYTOCHROME P450; DEXAMETHASONE; LIVER ENZYME; MIDAZOLAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; LIVER MICROSOME; MALE; MODEL; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLOTRIMAZOLE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME ACTIVATION; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 0033054009     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991772600     Document Type: Article

References (30)

1. Backman, J. T., Olkkola, K. T., Neuvonen, P. J. (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59: 7-13
2. Carlile, D. J., Zomorodi, K., Houston, J. B. (1997) Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab. Dispos. 25: 903-911
3. Debri, K., Boobis, A. R., Davies, D. S., Edwards, R. J. (1995) Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem. Pharmacol. 50: 2047-2056
4. Dedrick, R. L., Forester, D. D., Cannon, J. N., ElDareen, S. M., Mellett, L. B. (1973) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem. Pharmacol. 22: 2405-2417
5. Ghosal, A., Satoh, H., Thomas, P. E., Bush, E., Moore, D. (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab. Dispos. 24:940-947
6. Gorski, J. C., Hall, S. D., Jones, D. R., VandenBranden, M., Wrighton, S. A. (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47: 1643-1653
7. Guengerich, F. P. (1992) Characterization of human cytochrome P450 enzymes. FASEB J. 6: 745-748
8. Higashikawa, F., Murakami, T., Kaneda, T., Kato, A., Takano, M. (1999) Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate, in rats with differently modulated enzyme activities. J. Pharm. Pharmacol. 51: 67-72
9. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., Sugiyama, Y. (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38: 461-499
10. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Sugiyama, Y. (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17: 273-310
11. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., Sugiyama, Y. (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 147-171
12. Jayyoshi, Z., Muc, M., Erick, J., Thomas, P. E., Kelley, M. (1996) Catalytic and immunochemical characterization of cytochrome P450 isozyme induction in dog liver. Fundam. Appl. Toxicol. 31:95-102
13. Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., Watkins, P. B. (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90: 1871-1878
14. Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., Meyer, U. A. (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96
15. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J., Krahenbuhl, S. (1995) Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58: 20-28
16. Lee, P. C., Werlin, S. L. (1995) The induction of hepatic cytochrome P450 3A in rats: effects of age. Proc. Soc. Exp. Biol. Med. 210: 134-139
17. Lin, J. H., Chiba, M., Balani, S. K., Chen, I. W., Kwei, G. Y., Vastag, K. J., Nishime, J. A. (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24: 1111-1120
18. Lown, K. S., Kolars, J. C., Thummel, K. E., Barnett, J. L., Kunze, K. L., Wrighton, S. A., Watkins, P. B. (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22: 947-955
19. Mahnke, A., Roos, P. H., Hanstein, W. G., Chabot, G. G. (1996) In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. Biochem. Pharmacol. 51: 1579-1582
20. Montandon, B., Roberts, R. J., Fisher, L. J. (1975) Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J. Pharmacokinet. Biopharm. 3: 277-290
21. Olkkola, K. T., Backman, J. T., Neuvonen, P. J. (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55: 481-485
22. Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., Thummel, K. E. (1996) First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60: 14-24
23. Porter, T. D., Coon, M. J. (1991) Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 266: 13469-13472
24. Roberts, M. S., Rowland, M. (1986) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14: 227-260
25. Schmiedlin-Ren, P., Benedict, P. E., Dobbins, W. O., Ghosh, M., Kolars, J. C., Watkins, P. B. (1993) Cultured adult rat jejunal explants as a model for studying regulation of CYP3A. Biochem. Pharmacol. 46: 905-918
26. Tata, J. R. (1970) Coordination between membrane phospholipid synthesis and accelerated biosynthesis of cytoplasmic ribonucleic acid and protein. Biochem. J. 116: 617-630
27. Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Bacchi, C. E., Marsh, C. L., McVicar, J. P., Barr, D. M., Perkins, J. D., Carithers, R. L. (1994a) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271: 549-556
28. Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Bacchi, C. E., Marsh, C. L., McVicar, J. P., Barr, D. M., Perkins, J. D., Carithers, R. L. (1994b) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepaticCYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271: 557-566
29. Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Wilkinson, G. R. (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59: 491-502
30. Wrighton, S. A., Ring, B. J. (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11: 921-924